Angelina Jolie's case highlights the importance of knowing …
Treating breast cancer almost always involves surgery, and for …
A group of more than 120 cancer researchers and physicians took…
Updated: Thursday, 27 Dec 2012, 4:52 PM EST
Published : Thursday, 27 Dec 2012, 4:52 PM EST
ROCKVILLE, Md. (AP) - A Rockville company will study the feasibility of a new cancer medicine with the large pharmaceutical company AstraZeneca.
CytImmune Sciences Inc. and AstraZeneca made the announcement on Thursday.
The two companies will work together to see whether they can transmit cancer drugs on extremely small gold particles.
CytImmune works in developing nanomedicine, which uses tiny particles of gold to carry cancer therapies directly to the site of the disease. The company says gold nanoparticles have been used safely since the 1930s to treat patients with rheumatoid arthritis.
Dr. Lawrence Tamarkin, CytImmune's CEO, says the partnership aims to combine CytImmune's nanotechnology research with AstraZeneca's oncology compound to create a cancer therapy that may be widely applicable to solid tumors.
Ground rules for posting comments: No profanity or personal attacks. No racially charged comments. If it's not something you would say to someone's face, it's most likely inappropriate. Please comment on the subject of the story itself. If you do not follow these rules, we will remove your post. Repeat offenders will be banned from making future comments. Keep it civil, folks! WANE is not responsible for the content posted in this comment section.